Bristlecone Advisors’s Tvardi Therapeutics TVRD Stock Holding History

Bristlecone Advisors’s Portfolio TVRD Stock Details TVRD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-30	Closed	-$15K	–	266
2017 Q3	$15K	Buy	+30	New	+$15K	﹤0.01%	253

Other funds holding TVRD

RCP

Rho Capital Partners New York $20.4M AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

DGI

Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Bristlecone Advisors's TVRD Position: Q4 2017 in Review

Bristlecone Advisors sold out of Tvardi Therapeutics (TVRD) in Q4 2017, closing a stake of 30 shares — an estimated $15K sold.

Bristlecone Advisors first reported a position in TVRD in Q3 2017 and held it in 1 quarter. The position peaked at $15K in Q3 2017. 127 funds tracked by Wall St. Rank hold TVRD as of Q4 2017.

Bristlecone Advisors reported no remaining Tvardi Therapeutics position as of Q4 2017 after selling out during the quarter.
Bristlecone Advisors sold 30 Tvardi Therapeutics shares in Q4 2017, an estimated $15K.
Bristlecone Advisors first reported a position in Tvardi Therapeutics in Q3 2017 and held it in 1 quarter.
Bristlecone Advisors's Tvardi Therapeutics position peaked at $15K in Q3 2017.
127 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q4 2017.

Based on Bristlecone Advisors's 13F filing for Q4 2017, filed 30 Jan 2018.